Fatty Liver Patient Registry

NCT02298439 | Recruiting

• 1 other identifier: 13-6128-AE
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of the Non-Alcoholic Fatty Liver Disease (NAFLD) registry is to collect demographic and clinical data on patients being treated for NAFLD and to determine the factors affecting the progression of the disease as well as the success of different treatment strategies.

Conditions

Non-Alcoholic Fatty Liver Disease

Keywords

NAFLD

Outcome Measures

Primary Outcomes (1)

• Disease categorization

  Specific diagnosis of NAFLD: simple steatosis (SS), steatohepatitis (NASH), cirrhosis

  Baseline

Secondary Outcomes (3)

• Disease categorization

  at each clinic visit, up to 5 years

• Liver biopsy results

  at each clinic visit, up to 5 years

• Survival

  at each clinic visit, up to 5 years

Other Outcomes (10)

• Patient demography

  at each clinic visit, up to 5 years

• Anthropometry

  at each clinic visit, up to 5 years

• Macro- and micronutrient intake

  at each clinic visit, up to 5 years

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with Non-Alcoholic Fatty Liver Disease (NAFLD )which includes simple steatosis (SS) and non-alcoholic steatohepatitis (NASH) that being treated

You may qualify if:

• \- Patients being treated for NAFLD at the Toronto General Hospital NAFLD clinic

You may not qualify if:

• None

Sponsors & Collaborators

• University Health Network, Toronto: lead

Study Sites (1)

Toronto General Hospital

Toronto, Ontario, M5G 1Z5, Canada

RECRUITING

Related Publications (5)

• Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol. 2014 Feb 21;20(7):1712-23. doi: 10.3748/wjg.v20.i7.1712.

  PMID: 24587650 RESULT

• Monteiro J, Leslie M, Moghadasian MH, Arendt BM, Allard JP, Ma DW. The role of n - 6 and n - 3 polyunsaturated fatty acids in the manifestation of the metabolic syndrome in cardiovascular disease and non-alcoholic fatty liver disease. Food Funct. 2014 Mar;5(3):426-35. doi: 10.1039/c3fo60551e.

  PMID: 24496399 RESULT

• Allard JP, Aghdassi E, Mohammed S, Raman M, Avand G, Arendt BM, Jalali P, Kandasamy T, Prayitno N, Sherman M, Guindi M, Ma DW, Heathcote JE. Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study. J Hepatol. 2008 Feb;48(2):300-7. doi: 10.1016/j.jhep.2007.09.009. Epub 2007 Nov 20.

  PMID: 18086506 RESULT

• Raman M, Allard J. Non alcoholic fatty liver disease: a clinical approach and review. Can J Gastroenterol. 2006 May;20(5):345-9. doi: 10.1155/2006/918262.

  PMID: 16691301 RESULT

• Allard JP. Other disease associations with non-alcoholic fatty liver disease (NAFLD). Best Pract Res Clin Gastroenterol. 2002 Oct;16(5):783-95. doi: 10.1053/bega.2002.0330.

  PMID: 12406445 RESULT

MeSH Terms

Conditions

Non-alcoholic Fatty Liver Disease

Condition Hierarchy (Ancestors)

Fatty Liver; Liver Diseases; Digestive System Diseases

Study Officials

• Johane Allard, MD, FRCPC

  UHN

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Anastasia Teterina, PhD

CONTACT

416-340-4104; anastasia.teterina@uhnresearch.ca

Akilen Rajadurai, PhD, BSc

CONTACT

416-340-4104; arajadur@uhnresearch.ca

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 5 Years
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD, FRCPC

Study Record Dates

• First Submitted: October 24, 2014
• First Posted: November 24, 2014
• Study Start: October 1, 2013
• Primary Completion (Estimated): June 1, 2026
• Study Completion (Estimated): June 1, 2026
• Last Updated: November 2, 2022

Record last verified: 2022-11

Locations

CA (1)